Addex Therapeutics (ADXN) Common Equity: 2022-2025
Historic Common Equity for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $8.7 million.
- Addex Therapeutics' Common Equity fell 37.72% to $8.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $8.7 million, marking a year-over-year decrease of 37.72%. This contributed to the annual value of $11.0 million for FY2024, which is 762.48% up from last year.
- Per Addex Therapeutics' latest filing, its Common Equity stood at $8.7 million for Q2 2025, which was down 5.58% from $9.2 million recorded in Q1 2025.
- In the past 5 years, Addex Therapeutics' Common Equity ranged from a high of $14.0 million in Q1 2022 and a low of -$1.6 million during Q1 2024.
- Over the past 3 years, Addex Therapeutics' median Common Equity value was $7.8 million (recorded in 2025), while the average stood at $7.1 million.
- Data for Addex Therapeutics' Common Equity shows a peak YoY increase of 755.45% (in 2024) and a maximum YoY decrease of 135.74% (in 2024) over the last 5 years.
- Quarterly analysis of 4 years shows Addex Therapeutics' Common Equity stood at $5.1 million in 2022, then plummeted by 74.68% to $1.3 million in 2023, then soared by 755.45% to $11.0 million in 2024, then crashed by 37.72% to $8.7 million in 2025.
- Its Common Equity was $8.7 million in Q2 2025, compared to $9.2 million in Q1 2025 and $11.0 million in Q4 2024.